8-K: Cadrenal Therapeutics Announces Director Resignation and Sets Annual Meeting Date with Revised Proposal Deadlines

Cadrenal Therapeutics, Inc. announced the resignation of director Robert Lisicki and set the date for its 2025 annual meeting of stockholders, along with revised deadlines for stockholder proposals.

Summary

• Robert Lisicki, a Class II Director, resigned from the Board of Directors of Cadrenal Therapeutics, Inc., effective July 15, 2025.
• Mr. Lisicki's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.
• The 2025 annual meeting of stockholders is currently planned to be held on September 24, 2025.
• The record date for determining shareholders entitled to vote at the 2025 Annual Meeting is set as the close of business on July 28, 2025.
• Since the 2025 Annual Meeting is scheduled more than 30 days after the anniversary of the 2024 annual meeting, prior deadlines for stockholder proposals under Rule 14a-8 are no longer applicable.
• The revised deadline for stockholder proposals submitted pursuant to Rule 14a-8 for inclusion in the Company's proxy statement for the 2025 Annual Meeting is July 28, 2025.
• The deadline for timely notice of any director nomination or other proposal that stockholders intend to present at the 2025 Annual Meeting, but do not seek to have included in the proxy materials, is July 28, 2025.
• Shareholders intending to solicit proxies in support of director nominees other than the Company's nominees must provide notice as required by Rule 14a-19 under the Exchange Act by July 28, 2025.

Sentiment

Score: 6

Explanation: The document is largely neutral, detailing routine corporate governance events. The explicit statement that the director's resignation was not due to disagreement adds a slight positive nuance, indicating stability rather than internal conflict.

Positives

• The resignation of Robert Lisicki was explicitly stated not to be the result of any disagreement with the Company's operations, policies, or practices, suggesting a smooth transition and no underlying corporate conflict.

Future Outlook

The Company plans to hold its 2025 annual meeting of stockholders on September 24, 2025, and intends to set the record date for voting as July 28, 2025. The specific time and location of the meeting will be disclosed in the Company's Annual Meeting Proxy Statement for the 2025 Annual Meeting, which will be filed with the SEC.

Industry Context

This announcement reflects standard corporate governance practices for publicly traded companies, including managing board transitions and adhering to SEC regulations for annual shareholder meetings and proxy solicitations. The revised deadlines for stockholder proposals are a direct consequence of the annual meeting date being set more than 30 days after the anniversary of the prior year's meeting, a common occurrence that requires specific disclosure under SEC rules to ensure shareholder rights are maintained.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are impacted by the director resignation (though stated as amicable), the setting of the annual meeting date, and the revised deadlines for submitting proposals and nominations, which require timely action to participate in corporate governance.

Next Steps

• The Company will file its Annual Meeting Proxy Statement for the 2025 Annual Meeting with the SEC, which will include the time and location of the meeting.
• Shareholders must submit proposals by July 28, 2025, to be considered for inclusion in the proxy materials for the 2025 Annual Meeting.
• Shareholders must provide timely notice by July 28, 2025, for director nominations or other proposals not included in proxy materials, or for soliciting proxies for alternative nominees.

Key Dates

Keywords

Cadrenal Therapeutics, CVKD, SEC filing, 8-K, director resignation, annual meeting, stockholder proposals, corporate governance, Nasdaq